e-learning
resources
Amsterdam 2015
Wednesday, 30.09.2015
Cellular and molecular mechanisms of COPD and emphysema
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease
mahdia gholamnejad (Urmia, Islamic Republic of Iran), Mahdia Gholamnejad, Nasser Jahanbakhsh, Mohammad Hossein Rahimi-Rad, Mohammad Hassan Khadem Ansari, Shaker Salari Lak
Source:
International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Session:
Cellular and molecular mechanisms of COPD and emphysema
Session type:
Poster Discussion
Number:
5056
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
mahdia gholamnejad (Urmia, Islamic Republic of Iran), Mahdia Gholamnejad, Nasser Jahanbakhsh, Mohammad Hossein Rahimi-Rad, Mohammad Hassan Khadem Ansari, Shaker Salari Lak. Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease. Eur Respir J 2015; 46: Suppl. 59, 5056
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Increased serum level of apelin in chronic obstructive pulmonary disease
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Comparison of serum osteopontin levels in patients with exacerbations and stable chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases
Year: 2012
Serum levels of leptin and visfatin in chronic obstructive pulmonary disease
Source: International Congress 2015 – Different data in COPD
Year: 2015
Malondialdehyde level in chronic obstructive pulmonary disease exacerbations
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
Elevated sputum BPIFB1 levels correlate with progression of chronic obstructive pulmonary disease
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
Increased total serum levels of ghrelin and nesfatin in chronic obstructive pulmonary disease
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Biomarkers in the management of COPD
Source: Eur Respir Rev 2009; 18: 96-104
Year: 2009
Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Serum leptin levels in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 259s
Year: 2002
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Investigating COPD in longitudinal studies
Year: 2013
Clinical value of C-reactive protein in severe acute exacerbations of COPD
Source: Annual Congress 2005 - COPD - acute exacerbations
Year: 2005
Periostin levels in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
Prevalence of exacerbation in COPD patients with chronic bronchitis and association with elevated serum inflammatory biomarkers
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Relevance of hemoglobin A1c and acute exacerbations of chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Combined serum eosinophil count and procalcitonin level as a marker of bacterial infection in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Serum interferon-gamma levels in chronic obstructive pulmonary disease and asthma patients: correlation with respiratory parameters
Source: Eur Respir J 2001; 18: Suppl. 33, 75s
Year: 2001
Blood MCP-1 levels are increased in chronic obstructive pulmonary disease with prevalent emphysema
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
Recruitment of blood fibrocytes during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4 dependent pathway
Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease
Year: 2015
BNP level in patients with COPD exacerbations
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept